

CURRICULUM VITAE

Name: Niki Vassilaki

Work address: Hellenic Pasteur Institute, Molecular Virology laboratory,
Vas. Sofias Ave., 11521 Athens, Greece

Tel: +302106478875, +306974174747

E-mail: nikiv@pasteur.gr



PERSONAL DATA: Nationality: Greek, Date of Birth: 8/8/1975, Family status: Married with one child

EDUCATION:	DEGREE	YEARS
<p><u>B.Sc. in Biology</u> National and Kapodistrian University of Athens</p> <p>Bachelor thesis in Molecular Virology: "Expression and characterization of selected proteins of the Hepatitis C virus in <i>E. coli</i>". 1998-1999</p> <p>Faculty of Biology, Department of Biochemistry and Molecular Biology Supervisor Prof. D. Vassilacopoulou, Experimental study performed in Hellenic Pasteur Institute, Molecular Virology (head Prof. P. Mavromara)</p>	BSc (Grade: 8.4)	1995- 1999
<p><u>Ph.D in Molecular Virology</u> National and Kapodistrian University of Athens</p> <p>Title of PhD thesis: "Structural region of the Hepatitic C virus polyprotein. Molecular mechanisms of expression and function"</p> <p>Faculty of Biology, Department of Biochemistry and Molecular Biology Supervisor Prof. E. G. Fragoulis</p> <p>Experimental study performed in Hellenic Pasteur Institute, Molecular Virology Laboratory (head Prof. P. Mavromara), on the alternative translation initiation mechanisms of the Hepatitis C virus (HCV) core+1 open reading frame, the discovery of the expression of core+1/ARFP short protein in human hepatocytes and its biological and immunological properties</p>	Ph.D (Grade: 10)	2000- 2006
<p><u>Post-graduate courses:</u> Genetics, Biochemistry and Molecular Biology, Cellular Biology and Biophysics, Animal Physiology and Immunology</p> <p>University of Athens, Faculty of Biology</p>		2001

TRAINING

2004-2005, Basic and Advanced Light Microscopy & Image Analysis, IP-EAMNET workshop: Plateforme Imagerie Dynamique **Institut Pasteur Paris** (21-25 June 2004) and **Hellenic Pasteur Institute** (17-22 May 2004 and 18-22 April 2005)

2006-2007, Subgenomic and infectious systems for HCV replication in human cultured hepatocytes: **University of Heidelberg**, Department of Infectious Diseases, Molecular Virology, Heidelberg, Germany

2005&2007, Microarray Technology EMBO practical course (20-25 June 2005) and hands-on experience for research project (2007) in Codelink platform: **EMBL** (European Molecular Biology Laboratory), Genomics Core Facilities, Heidelberg, Germany:

05/2016, Course on high content assay based on automated microscopy for chemical compound screening and RNA interference (RNAi): **Institut Pasteur Korea**. Experience on HBV cell culture systems

ACADEMIC POSITIONS

2006-2007 **Invited Post-doctoral fellow** in Molecular Virology, Department of Infectious Diseases headed by *Prof. R. Bartenschlager*, University of Heidelberg (Germany)

By applying the HCV infectious clone in cell culture and in Alb-uPA/SCID mice with chimeric human liver, N. Vassilaki studied the role of core+1 expression and core cis-acting RNA structural elements on virus proliferation.

06/2007-07/2016 **Researcher D** (Lecturer level) in Molecular Virology, Hellenic Pasteur Institute

07/2016-current **Researcher C** (Assistant Professor level) in Molecular Virology, Hellenic Pasteur Institute

RESEARCH FOCUS

Molecular biology of *Flaviviridae* viruses HCV (Hepatitis C), DENV (Dengue), YFV (Yellow Fever) and ZIKV (Zika) and of *Hepadnavirus* HBV with main focus on mechanisms of viral replication and pathogenesis as well as on molecular mechanisms of action of replication inhibitors:

- Metabolic basis of the association between hepatotropic viral replication (HCV, DENV, YFV and HBV) and oxygen signaling and the role of this interaction in viral pathogenesis and in the efficacy of direct-acting anti-virals

Vassilaki et al. J Virol. 2013; Vassilaki N. and Frakolaki E. Microbes Infect. 2017; Frakolaki et al. Cells 2018; Frakolaki et al. Institut Pasteur International Network Symposium 2016

- Role of L-Dopa Decarboxylase, a recently identified PI3K binding partner, in *Flaviviridae* virus infections

Vassiliou et al. Biochimie 2019; Frakolaki et al. accepted in Cells 2019

- Broad-spectrum inhibitors against *Flaviviridae* viruses (HCV, DENV, YFV, ZIKV) under culture conditions simulating tissue normoxic and metabolic microenvironment

Giannakopoulou et al. MedChemComm 2019; Frakolaki et al. International Symposium on HCV and related viruses 2018

- Novel potent and safe HCV inhibitors from collections of synthetic analogues and natural products and characterization of their molecular mechanisms of action

Zoidis et al. MedChemComm 2016; Lougiakis et al. Chem Biol Drug Des 2017; Ramsis et al. Arch Pharm (Weinheim) 2018; Leila A. et al. ACS Omega 2019

- Role of core cis-acting RNA elements in HCV RNA translation and replication in cell culture models and in humanized mice

Vassilaki et al. J Virol. 2008

- Alternative translation initiation mechanisms of the HCV core+1 open reading frame, discovery of the expression of the HCV core+1/ARFP short protein in cultured human hepatocytes and study on its regulatory role in viral pathogenesis

Varaklioti A., Vassilaki N. et al. J Biol Chem 2002, Vassilaki and Mavromara J Biol Chem 2003, Vassilaki et al. Febs J 2007, Vassilaki et al. Virus Res 2008, Vassilaki et al. J Gen Virol 2008, Boumlic,

RESEARCH PROGRAMS FUNDED

Coordinator of grants

2006-2007 DAAD, German Academic Exchange Post-doctoral Research Grant: "*Role of hepatitis C virus core+1 open reading frame and core cis-acting RNA elements in hepatitis C virus life cycle*"

The research study was performed in the Department of Molecular Virology (University of Heidelberg, Germany)

2013-2014 LATSIS Public Benefit Foundation research grant: "Development and exploitation of a more true-to-life novel infectious cell culture system for HCV growth for the characterization of new anti-HCV drugs"

International collaborators: Prof. R. Bartenschlager (Department of Infectious Diseases, Heidelberg University, Germany)

National collaborators: Prof. A. L. Skaltsounis, Prof. N. Aligiannis and Dr A. Argyropoulou (Faculty of Pharmacy, University of Athens, Department of Pharmacognosy and Chemistry of Natural Compounds), Prof. G. Zoidis (Faculty of Pharmacy, University of Athens, Department of Pharmaceutical Chemistry), Prof. M. Hatzopoulou-Cladaras and Dr I. Vallianou (School of Biology, Aristotle University of Thessaloniki, Department of Genetics, Development and Molecular Biology), Prof. J. Koskinas (2nd Department of Internal Medicine, Medical School of Athens, Hippokration Hospital, Athens), Prof. P. Mavromara (Hellenic Pasteur Institute),

2015-2017 International Pasteur Network Program ACIP: "Identification of broad-spectrum naturally derived inhibitors against hepatotropic viruses (DENV, YFV, HBV) under culture conditions simulating liver normoxic and metabolic microenvironment. The interplay between virus and hepatic normoxia as a possible disease determinant"

Collaborating Institut Pasteur (IP) partners: Dr C. Neuveut (IP Paris, Unité des Hépacivirus et Immunité Innée), Dr M.P. Windisch (IP Korea, Applied Molecular Virology), Prof. P. Mavromara (HPI, Molecular Virology), Dr H. Boleti (HPI, Light Microscopy Unit).

Other collaborators: Prof. R. Bartenschlager (Department of Infectious Diseases, Heidelberg, Germany), Prof. A. L. Skaltsounis and Prof. Zoidis (Faculty of Pharmacy, Athens, Greece)

2016 International Pasteur Network travel grant Calmette & Yersin Nov. 2016: "Broadly active anti-virals against Hepatitis B Virus in a cell model adapted to liver normoxia" Traineeship of the PhD student E. Frakolaki in the group of Molecular Biology of Hepatitis B virus, Department of Virology, Institut Pasteur Paris, France.

Coordinators: Dr N. Vassilaki and Dr C. Neuveut (IP Paris, Unité des Hépacivirus et Immunité Innée)

2017-2018 Asklepios Gilead Sciences Hellas grant 2016

"Characterization of new synthetic and natural compounds with broad-spectrum anti-viral activity as inhibitors of Hepatitis B virus in a cell culture model simulating the in vivo normoxic microenvironment. Importance of liver normoxia for HBV replication and the efficiency of inhibitors"

Collaborators: Dr C. Neuveut (IP Paris, Unité des Hépacivirus et Immunité Innée), Dr M.P. Windisch (IP Korea, Applied Molecular Virology), Prof. A. L. Skaltsounis, Prof. G. Zoidis and Dr V. Myrianthopoulos (Faculty of Pharmacy, University of Athens, Greece), Dr H. Boleti (HPI, Light

Microscopy Unit)

2017-2018 Empeirikeion Foundation Research Grant 2016

"Design, synthesis and biological characterization of novel broadly active inhibitors against Hepatitis C virus and the related re-emerging Flaviviruses Zika, Dengue and Yellow Fever. Validation in a cell-based infectious model simulating *in vivo* conditions of the tissue"

Coordinators: Dr N. Vassilaki (Hellenic Pasteur Institute, Athens, Greece) and Prof. G. Zoidis (Faculty of Pharmacy, University of Athens, Greece), Collaborators: Dr V. Myrianthopoulos (Faculty of Pharmacy, University of Athens, Greece), Dr M.P. Windisch (IP Korea, Applied Molecular Virology), Prof. R. Bartenschlager (Department of Infectious Diseases, Heidelberg, Germany)

2018-2019 IKY (State Scholarships Foundation) and the European Social Fund (ESF) and the Public Investments grant for the research project "Evaluation of novel inhibitors of Hepatitis C and related viruses and biomarkers of response to anti-viral therapeutics". Thesis project of the PhD student Efseveia Frakolaki.

Principal Investigator: Dr N. Vassilaki

Jan-May 2018 Erasmus+ Traineeship for the research project "Lipophilic heterocyclic chelating agents (acetohydroxamic acids) that are broadly active against Flaviviridae viruses. Evaluation in enzymatic assays for viral metallo-enzymes from Flaviviruses and Arenaviruses; Co-relation with inhibitory activities determined in sub-genomic replicon transfected cells", Traineeship of the Biologist Giorgos Niotis, in the laboratory Architecture et Fonctions des Macromolécules Biologiques (AFMB), UMR 7257 du CNRS et de l'Université Aix-Marseille, France

Principal Investigators: Dr Niki Vassilaki (Molecular Virology, HPI) and Dr Bruno Canard - Prof. Nicolas Papageorgiou (AFMB, UMR 7257 du CNRS et de l'Université Aix-Marseille, France)

2019-2020 Asklepios Gilead Sciences Hellas grant 2018

"Aromatic L-aminoacid decarboxylase: A new metabolic factor associated with Hepatitis C virus infection and the development of Hepatocellular Carcinoma",

Collaborators: Dr D. Vassilacopoulou (Faculty of Biology, University of Athens, Greece), Prof. J. Koskinas (2nd Department of Internal Medicine of Athens University Medical School and Hippokration General Hospital), Prof. N. Pouli and P. Marakos (Faculty of Pharmacy, University of Athens, Greece), Dr H. Boleti (HPI, Light Microscopy Unit)

Principal investigator of subprojects in research grants

2016-2017 HCV related subproject of the Asklepios Gilead Sciences Hellas grant 2015 concerning the evaluation against HCV of novel lipophilic heterocyclic chelating agents: "Design, synthesis and biological evaluation of novel lipophilic heterocyclic chelating agents against Hepatitis C virus"

Coordinator: Prof. G. Zoidis, Faculty of Pharmacy, University of Athens

2013-2015 Subcontracting project of the National Grant BIONIAN, Greek Life Sciences Cluster 2013-2015/ General Secretariat for Research and Technology (GSRT)- European Social Fund (ESF) and the Greek State, within the National Strategic Reference Framework (NSRF) "Novel inhibitors of HCV growth and biomarkers related to HCV pathogenesis and response to therapeutics. A) A set of novel inhibitors of Hepatitis C Virus growth. B) Evaluation of microRNAs as biomarkers for HCV pathogenesis and response to anti-virals".

- 2013-2015** **Two subprojects of the action KRIPIS I: Development grants for research institutions 2013-2015/** General Secretariat for Research and Technology (GSRT)- European Social Fund (ESF) and the Greek State, within the National Strategic Reference Framework (NSRF): "Infectious and neurodegenerative diseases in the 21st century: From the study of basic mechanisms to the development of translational research and cutting-edge methodologies aiming to effective diagnosis, prevention and therapy" Title of subprojects: "Development and exploitation of a more true-to-life novel infectious cell culture system for HCV growth. Role of circulating microRNAs as prognostic biomarkers for HCV-associated hepatocellular carcinoma"
Coordinator: Dr E. Karagouni (Hellenic Pasteur Institute)
- 2017-2019** **Subproject of the action KRIPIS II: Development grants for research institutions 2017-2019:** "Infectious, autoimmune and neurodegenerative diseases: study of pathogenic mechanisms and development of diagnostic, prognostic and therapeutic strategies". Title of subproject: "Identification of broadly effective inhibitors against viruses of *Flaviviridae* family and Hepatitis B virus"
Coordinator: Dr E. Karagouni (Hellenic Pasteur Institute)
- 2019-2021** **Subproject of the action ESFRI- European Strategy Forum for Research Infrastructures, National Research & Innovation Infrastructures EATRIS-GR:** Infrastructure for Preclinical and Early-Phase Clinical Development of Drugs, Therapeutics and BioMedical Devices. Title of subproject: "Application of advanced in vitro viral models for the preclinical evaluation of small molecule inhibitors and other drugs against Flaviviruses (Dengue, Yellow Fever, Zika)"
Coordinator: Paschalis Sideras (Biomedical Research Foundation Academy of Athens)

Participation in research grants as collaborating researcher

- 2018-2019** **Asklepios Gilead Sciences Hellas grant 2017:** "Design, synthesis and biological evaluation of new bivalent inhibitors of NS5A with selective anti-HCV activity". Coordinator: Prof. G. Zoidis, Faculty of Pharmacy, University of Athens
- 2018** **Single RTDI State Aid Action RESEARCH - CREATE - INNOVATE/ EPAnEK,** Greek General Secretariat for Research and Technology (GSRT): "Development of peptide-based nanovaccines against Leishmaniasis (NanoVacLeish)".
Principal Investigator: Dr E. Karagouni, Participants: Hellenic Pasteur Institute (Coordinator), Centre for Research and Technology Hellas, Gerolymatos International S.A.
- 2013-2015** **ARISTEIA: Oncohepcvir/** Greek General Secretariat for Research and Technology (GSRT): "The role of oncogenic viruses in the pathogenesis of hepatocellular carcinoma: The biological function of HCV core/core+1 proteins to the development of liver cancer."
Coordinator: Prof. P. Mavromara (Molecular Virology, HPI, Athens, Greece).
N. Vassilaki: Principal Investigator of the subproject "Elucidating the contribution of HCV core+1/ARFP/F protein to viral pathogenesis using mRNA/miRNA expression profiling of hepatocytes that support the replication of wild-type or core+1 mutant viruses (carrying non-sense mutations abolishing core+1 ORF expression)"
- 2013-2015** **THALES/** General Secretariat for Research and Technology (GSRT): "Mechanisms of signal transduction and gene expression in hepatocellular carcinoma"
Coordinator: G. Mosialos, collaborator Prof. M. Hatzopoulou-Cladaras (Department of Genetics, Faculty of Biology, Aristotle University of Thessaloniki)
- 2006-2007** **Program Transversal de Recherche (PTR 2003-2005) -International Pasteur Network:**

"Implications of HCV diversity in the diagnosis and pathogenesis of virus infection in Eastern Europe, SE Asia and Central Africa". Participating in studies on the estimation of prevalence of anti-core and anticore+1/ARFP antibodies in HCV-positive blood donors from Cambodia using home-made reagents. Analysis of the importance of synonymous mutations that likely favor the production of the alternative open reading frame protein during hepatitis C virus infection of these the Cambodian patients.

Coordinator: Prof P. Mavromara (Molecular Virology, HPI, Athens, Greece). Collaborators: Pasteur Institute of Paris and Pasteur Institutes of Cambodia, Vietnam, St. Petersburg (Russia) and Dakar (Senegal).

2006-2008 European integrated project COMPUVAC (FP6-COMPUVAC- LSHB-CT-2004):

"Rational design and standardized evaluation of novel genetic vaccines" Participating in studies on microarray analysis of gene expression profiling of dendritic cells upon *in vivo* exposure to candidate vaccine vectors: defective virus-based vectors (Adenovirus, Modified Vaccinia Ankara, Herpes Simplex Type 1-based amplicons), virus-like particles (AP205 bacteriophage, Moloney murine leukemia retrovirus MMLV, murine polyoma virus MPyV and murine pneumotropic virus MPtV) as well as mycobacterium bovis (BCG).

Coordinator: Prof. D. Klatzmann (Biotherapy at Pitié-Salpêtrière hospital, Biotechnology, France). Principal investigator in HPI: Dr P. Mavromara

RESEARCH COLLABORATIONS:

International: *Prof. R. Bartenschlager* (Department of Molecular Virology, Heidelberg University, Germany), *Dr M.P. Windisch* (Applied Molecular Virology, Institut Pasteur Korea, Seoul), *Dr Christine Neuveut* (CR1 INSERM, Unité des Hépacivirus et Immunité Innée, Institut Pasteur Paris), *Dr A. Budkowska* (Unité des Hépacivirus et Immunité Innée, Institut Pasteur Paris, CNRS URA 3015, Paris), *Dr A.-B. Failloux* (Arboviruses and Insect Vectors, Institut Pasteur Paris), *Dr Amadou Sall* (Laboratory of arboviruses and viral haemorrhagic fevers, Institut Pasteur de Dakar, Senegal), *Dr M. Goreti Rosa Freitas* (Mosquitoes Lab, Instituto Oswaldo Cruz-FIOCRUZ Rio de Janeiro, Brazil), *Dr K. Okamoto* (Human Genome and Stem Cell Research Center, Univ. of Sao Paulo), *Dr B. Canard* and *Prof. N. Papageorgiou* (Architecture et Fonctions des Macromolécules Biologiques, CNRS et de l'Université Aix-Marseille) *Prof. Philip Meuleman* (Ghent University, Belgium), *Prof. T. Baumert*, *Dr Mirjam Zeisel* (Inserm, U1110, Strasbourg, France), *Prof. M. Niepmann* (Institute of Biochemistry, School of Medicine, Giessen, Germany), *Dr Philippe Roingard* (Inserm U1259, Université de Tours et CHRU de Tours, France), *Dr G. Koutsoudakis* (CIBERehd, Barcelona, Spain), *Dr Vladimir Benes* (EMBL Genomics Core Facilities), *Prof. Dr. Ashraf H. Abadi* (Faculty of Pharmacy and Biotechnology, German University in Cairo, Egypt).

National: *Prof. A.L. Skaltsounis* (Department of Pharmacognosy and Chemistry of Natural Compounds, Faculty of Pharmacy, Athens University), *Prof. G. Zoidis* (Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Athens University), *Prof. P. Marakos* and *Prof. N. Pouli* (Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Athens University), *Prof. M. Hatzopoulou-Cladaras*, *Dr I. Vallianou* (Department of Genetics, Faculty of Biology, University of Thessaloniki), *Prof. J. Koskinas* (2nd Department of Internal Medicine of Athens University Medical School and Hippokraton General Hospital), *Prof. G. Simos*, *Prof. P. Liakos* (Laboratory of Biochemistry, School of Medicine, University of Thessaly), *Dr A. Mentis*, *Dr A. Kalliaropoulos* (Medical Microbiology, HPI), *Dr H. Boleti* (Intracellular Parasitism, HPI), *Dr D. Smirlis* (Molecular Parasitology, HPI)

AWARDS - DISTINCTIONS

- 1996-1998** Awards and Scholarships from the State Scholarships Foundation for the academic years 1995-1996, 1996-1997 and 1997-1998
- 2003, 2004, 2008** 10th, 11th and 15th International Symposium on Hepatitis C Virus and Related Viruses Travel Awards
- 2004-2006** PhD thesis fellowship from the Hellenic Pasteur Institute for the study on "Molecular mechanisms of expression and function of the HCV core+1 protein"
- 2008** Federation of European Microbiological Societies (FEMS) Young Scientist Meeting Grant 2008 for presentation at the 14th International Congress of Virology of International Union of Microbiological Societies (Istanbul, Turkey, 10-15 Aug. 2008): "*Exploring the importance of the hepatitis C virus core RNA secondary structure and core+1 reading frame expression for viral RNA translation and replication*", of Vassilaki N., Friebe P., Paranhos-Baccalà G., Mavromara P. and Bartenschlager R.
- 2010** Federation of European Microbiological Societies (FEMS) Young Scientist Meeting Grant 2010 for oral presentation at the 4th European Congress of Virology (Cernobbio, Italy, 7-11 Apr. 2010): "*Oxygen tension modulates hepatitis C virus proliferation*", of Vassilaki N., Kalliampakou K.I., Kotta-Loizou I., Smirlis D., Bartenschlager R. and Mavromara P.
- 2012** Poster presentation award from the 63rd Conference of the Hellenic Society for Biochemistry and Molecular Biology (HSBMB) 2012 for the study: "*Low Oxygen Tension Enhances Hepatitis C Virus Replication*", of Vassilaki N., Kalliampakou K.I., Kotta-Loizou I., Befani C., Liakos P., Simos G., Mentis A.F., Kalliaropoulos A., Doumba P.P., Smirlis D., Bauhofer O., Poenisch M., Windisch M.P., Lee M.E., Koskinas J., Bartenschlager R. and Mavromara P.
- 2016** The article "*Novel indole-flutimide heterocycles with activity against influenza PA endonuclease and hepatitis C virus*", in Med. Chem. Comm. 2016, Vol.7, No3, p.447-456, of Zoidis G., Giannakopoulou E., Stevaert A., Frakolaki E., Myrianthopoulos V., Fytas G., Mavromara P., Mikros E., Bartenschlager R., Vassilaki N.* and Naesens L.* (*: PI), was featured as: a) New Talent Europe, b) 2016 MedChemComm Hot Article and c) Front cover
- 2016** Principal investigator of the International Pasteur Network travel grant Calmette & Yersin awarded to the team member E. Frakolaki (PhD student) for research at Institut Pasteur Paris on "*Broadly active anti-virals against Hepatitis B Virus in a cell model adapted at liver normoxia*", and training in the Hepatitis B virus cell-culture based infectious system at Institut Pasteur Paris
- 2016** Institut Pasteur International Network Symposium 2016 (*From basic science to biomarkers and tools in Global Health*, Paris, France, 29 Nov. - 2 Dec., 2016) Travel Grant for the presentation: "*The interplay between Flaviviridae viruses and hepatic normoxia determines viral replication levels and response to therapeutics*", of Frakolaki E., Giannakopoulou E., Feuillet-Cadenne N., Kaimou P., Niotis G., Bartenschlager R. Mavromara P., Zoidis G., Windisch M., Neuveut C. and Vassilaki N.
- 2016** Two awards for best trainees' performance during the course 'High Content Assay for Drug Screening and Target discovery Using RNAi Technology', Institut Pasteur Korea, 9-13 May, 2016
- 2017** Best poster award 17th Hellenic Symposium on Medicinal Chemistry (17th HSMC).

Thessaloniki, Greece. 01-03 June 2017. "*Broadly effective metal chelators, as influenza PA endonuclease and hepatitis c virus inhibitors*". Giannakopoulou E., Stevaert A., Frakolaki E., Myriantopoulos V., Mikros E., Bartenschlager R., Vassilaki N., Naesens L. and Zoidis G.

- 2018** Invited Co-Chair at the 25th International Symposium on Hepatitis C Virus and Related Viruses (HCV2018, Dublin, Ireland). Session: Emerging and Related Viruses
- 2018** Best Oral Presentation Award, 4th Meeting of Postgraduate and Postdoctoral Researchers of Hellenic Pasteur Institute. "*Interaction between tissue normoxia and Dengue Virus replication*". Moraiti M., Frakolaki E., Kolaitis N., Kaimou P., Kalliampakou A., Karampetsou K., Dotsika E., Vassilacopoulou D., Mavromara P., Bartenschlager R. and Vassilaki N.
- 2019** The proposal "*Hepatotropic Viruses under Liver Normoxia: Identifying Metabolic Determinants of Disease and Characterizing Novel Antivirals*", acronym HEPVIROXIA (P.I. Niki Vassilaki) passed successfully the 1st phase (score 84.2/100) and was positively evaluated at the 2nd phase (score 82/100) of the First Call for Hellenic Foundation for Research and Innovation Research Projects To support Faculty members and Researchers.

ACADEMY MEMBERSHIPS

- **Reviewer:** International journals 'Journal of General Virology', 'Virus Research', 'Biochimie', 'International Journal of Molecular Sciences', 'International Journal of Environmental Research and Public Health' and 'IUBMB Life'.
- **Member:** 'Hellenic Society for Biological Sciences', 'Hellenic Society of Biochemistry and Molecular Biology', 'Scientific Committee of the Hellenic Society of Virology', 'Hellenic Association for the Study of Liver'
- **Member of lecturer body** in 2 Postgraduate programs of Athens University: Lectures "Molecular basis of viral diseases and their treatment" (program *Clinical biochemistry - Molecular diagnostics*), "Viruses as tools for vaccines, diagnosis and drug discovery" (program *Microbial Biotechnology*)
- **Invited presentation to international workshop** "Modern Methods of Light Microscopy and Applications in Biomedical Research and Diagnosis" (Hellenic Pasteur Institute, April 2005)

TEACHING ACTIVITIES

Participation in a 3-member PhD Thesis advisory committee (PhD student Efseveia Frakolaki) and **two 7-member PhD Thesis committees** (PhD Katerina Kassela, PhD Savvina Moustafa)

Supervision of:

Undergraduate diploma theses

- "Characterizing the biological function of the Hepatitis C virus core/core+1 protein" Panagiotis Sakellariou, Diploma thesis 2013, Faculty of Biology, University of Athens, Department of Biochemistry and Molecular Biology
- "Evaluating novel inhibitors of Hepatitis C virus proliferation" Marios Dimitriou, Diploma thesis 2015, Faculty of Biology, University of Athens, Department of Biochemistry and Molecular Biology

- Study of natural and semisynthetic compounds for their inhibitory activity against the proliferation of Hepatitis C Virus and related Flaviviruses" Konstantinos Kelepouras, Diploma thesis 2017, Faculty of Biology, University of Athens, Department of Biochemistry and Molecular Biology
- "Evaluation of replication inhibitors against viruses of the *Flaviviridae* family and characterization of their mechanisms of action by analysis of resistance mutations", Giorgos Niotis, Diploma thesis 2017, Faculty of Biology, University of Athens, Department of Genetics and Biotechnology
- "Evaluating broadly active inhibitors of viral replication and characterizing their mechanism of action at the genetic level through the study of adaptive changes in the virus genome and the host cell" Christos Caracostas, Diploma thesis 2019, Faculty of Biology, University of Athens, Department of Genetics and Biotechnology
- "Study of the interaction between viral replication and cellular metabolism under conditions of tissue normoxia (low oxygen) and in relation to L-Dopa decarboxylase" Nikolaos Kolaitis, Diploma thesis 2017- , Faculty of Biology, University of Athens, Department of Biochemistry and Molecular Biology
- "Association between hepatotropic viruses and tissue normoxia: studying the implicated cellular factors, including L-Dopa decarboxylase, and the impact on the efficiency of anti-virals" Vassilis Siozos, Diploma thesis 2018- , Faculty of Biology, University of Athens, Department of Biochemistry and Molecular Biology

Master theses

- "Studying cellular energetic metabolism and viral replication in cultured cells infected with *Flaviviridae* viruses under conditions of liver normoxia and in relation to L-Dopa decarboxylase", Panagiota Kaimou, Master thesis 2016-2018, Faculty of Biology, University of Athens, Department of Biochemistry and Molecular Biology, Postgraduate studies program Clinical Biochemistry - Molecular Diagnostics (Molecular Basis of Human Diseases)
- "Molecular mechanisms determining the relationship among viral infection, tissue normoxia and L-Dopa decarboxylase for hepatotropic viruses" Maria Moraiti, Master thesis 2017- , Faculty of Biology, University of Athens, Department of Biochemistry and Molecular Biology, Postgraduate studies program Clinical Biochemistry - Molecular Diagnostics (Molecular Basis of Human Diseases)
- "The importance of L-Dopa decarboxylase as a metabolic determinant of viral replication and pathogenesis" Anna Chalari, Master thesis 2018- , Faculty of Biology, University of Athens, Department of Biochemistry and Molecular Biology, Postgraduate studies program Clinical Biochemistry - Molecular Diagnostics (Molecular Basis of Human Diseases)

PhD theses

- "Evaluation of novel inhibitors of Hepatitis C virus and biomarkers of response to anti-viral therapeutics" Efseveia Frakolaki, PhD thesis 2014-2019, Faculty of Biology, University of Athens, Department of Genetics and Biotechnology, 3-member advisory committee: Prof. A. M. Pappas, Dr N. Vassilaki, Prof. P. Mavromara
- Co-supervision of the PhD theses of Anissa Boumlic (2006) and Ioly Kotta-Loizou (2009-2012)

Teaching in Postgraduate studies programs

- 2015-current: Lectures "Molecular basis of viral diseases and their treatment", Inter-University Postgraduate studies program CLINICAL BIOCHEMISTRY - MOLECULAR DIAGNOSTICS, in the context of the course Molecular Basis of Human Diseases, Faculty of Biology, University of Athens
- 2015-current: Lectures "Viruses as tools for vaccine construction, diagnosis and drug discovery", Postgraduate studies program MICROBIAL BIOTECHNOLOGY, Faculty of Biology, University of Athens

Teaching in laboratory exercises, courses

- 2001-2005: Participation as assistant in undergraduate laboratory exercises of Biochemistry, Department of Biochemistry and Molecular Biology, Faculty of Biology, University of Athens
- 04/2005: Invited lecturer at practical exercises of the international workshop "Modern Methods of Light Microscopy and Applications in Biomedical Research and Diagnosis" (Hellenic Pasteur Institute).

Science and Society

Teaching high school students at Hellenic Pasteur Institute with lectures and practical exercises in Molecular Biology and Virology techniques

PUBLICATIONS

Full length articles

1. Varaklioti A., **Vassilaki N.**, Georgopoulou U., and Mavromara P. *Alternate translation occurs within the core-coding region of the hepatitis C viral genome.* **J Biol Chem** **2002**, 277, 17713-17721. doi: 10.1074/jbc.M201722200 PMID: 11884417 (IF: 6.696)
2. **Vassilaki N.** and Mavromara P. *Two alternative mechanisms are responsible for the synthesis of HCV ARFP/F/core+1.* **J Biol Chem** **2003**, 278, 40503–40513. doi: 10.1074/jbc.M305504200 PMID: 12874283 (IF: 6.482)
3. **Vassilaki N.**, Khalili S. and Mavromara P. *HCV-associated hepatocellular carcinoma.* In **Viral Oncogenesis** **2006** (Tognon M, eds), pp 145-181. Research Signpost Press, Kerala, India.
4. **Vassilaki N.**, Boleti H., Mavromara P. *Expression studies of the core+1 protein of the hepatitis C virus 1a in mammalian cells. The influence of the core protein and proteasomes on the intracellular levels of core+1.* **FEBS J.** **2007**, 274, 4057-4074. doi: 10.1111/j.1742-4658.2007.05929.x PMID: 17651444 (IF: 3.396)
5. **Vassilaki N.**, Kalliampakou K.I. and Mavromara P. *Differences in the expression of the hepatitis C virus core+1 open reading frame between a nuclear and a cytoplasmic expression system.* **J Gen Virol** **2008**, 89, 222-231. doi: 10.1099/vir.0.83260-0 PMID: 18089746 (IF: 3.092)
6. **Vassilaki N.**, Boleti H. and Mavromara P. *Expression studies of the HCV-1a core+1 open reading frame in mammalian cells.* **Virus Res** **2008**, 133, 123-135. doi: 10.1016/j.virusres.2007.10.019 PMID: 18243391 (IF: 2.429)

7. **Vassilaki N.**, Friebe P., Meuleman P., Kallis S., Kaul A., Paranhos-Baccalà G., Leroux-Roels G., Mavromara P. and Bartenschlager R. *Role of hepatitis C virus core+1 open reading frame and core cis-acting RNA elements in viral RNA translation and replication.* **J Virol** **2008**, 82, 11503-15. doi: 10.1128/JVI.01640-08 PMID: 18799568 PMCID: PMC2583673 (IF: 5.308)
8. **Vassilaki N.*** and Mavromara P.* *The HCV ARFP/F/core+1 protein: production and functional analysis of an unconventional viral product.* **IUBMB Life** **2009**, 61, 739-52. doi: 10.1002/iub.201 PMID: 19548320 (IF: 3.578)
* **Corresponding authors**
9. Boumlic A., Nominé Y., Charbonnier S., Dalagiorgou G., **Vassilaki N.**, Kieffer B., Travé G., Mavromara P., Orfanoudakis G. *Prevalence of intrinsic disorder in the hepatitis C virus ARFP/Core+1/S protein.* **FEBS J** **2010**, 277, 774-89. doi: 10.1111/j.1742-4658.2009.07527.x. PMID: 20067524 (IF: 3.129)
10. Boumlic A., **Vassilaki N.**, Dalagiorgou G., Kochlios E., Kakkanas A., Georgopoulou U., Markoulatos P., Orfanoudakis G., Mavromara P. *Internal translation initiation stimulates expression of the ARF/core+1 open reading frame of HCV genotype 1b.* **Virus Res** **2011**, 155, 213-20. doi: 10.1016/j.virusres.2010.10.007 PMID: 20959129 (IF: 2.941)
11. Budkowska A., Kakkanas A., Nerrienet E., Kalinina O., Maillard P., Horm S.V., Dalagiorgou G., **Vassilaki N.**, Georgopoulou U., Martinot M., Sall A.A., and Mavromara P. *Synonymous mutations in the core gene are linked to unusual serological profile in hepatitis C virus infection.* **PLoS One.** **2011**, 6:e15871. doi: 10.1371/journal.pone.0015871. PMID: 21283512 PMCID: PMC3017048 (IF: 4.092)
12. Dalagiorgou G., **Vassilaki N.**, Foka P., Boumlic A., Kakkanas A., Kochlios E., Khalili S., Aslanoglou E., Veletza S., Orfanoudakis G., Vassilopoulos D., Hadziyannis S., Koskinas J., Mavromara P. *High Levels of HCV core+1 Antibodies in HCV Patients with Hepatocellular Carcinoma.* **J Gen Virol.** **2011**, 92: 1343-51. doi: 10.1099/vir.0.023010-0. PMID: 21307221 (IF: 3.363)
13. Kotta-Loizou I., **Vassilaki N.***, Pissas G., Kakkanas A., Bakiri L., Bartenschlager R. and Mavromara P.* *Hepatitis C virus core+1/ARF protein decreases hepcidin transcription through an API binding site.* **J Gen Virol.** **2013**, 94, 1528-34. doi: 10.1099/vir.0.050328-0. PMID: 23580428 (IF: 3.529)
* **Corresponding authors**
14. **Vassilaki N.***, Kalliampakou K.I., Kotta-Loizou I., Befani C., Liakos P., Simos G., Mentis A.F., Kalliaropoulos A., Doumba P.P., Smirlis D., Foka P., Bauhofer O., Poenisch M., Windisch M.P., Lee M.E., Koskinas J., Bartenschlager R. and Mavromara P.* *Low oxygen tension enhances hepatitis C virus replication.* **J Virol.** **2013**, 87, 2935-48. doi: 10.1128/JVI.02534-12. PMID: 23269812 PMCID: PMC3571389 (IF: 4.648)
* **Corresponding authors**
15. Robotis J.F.* and **Vassilaki N.*** *Viral Hepatitis.* In *Reference Module in Biomedical Sciences*, **2014**, edited by M. Caplan, Elsevier. doi: 10.1016/B978-0-12-801238-3.05401-5.
* **Corresponding authors**

16. Kotta-Loizou I., Karakasiliotis I., **Vassilaki N.**, Sakellariou P., Bartenschlager R. and Mavromara P. *Expression of the novel HCV core+1/ARF protein in the context of JFH1-based replicons.* **J Virol.** **2015**, 89:5164-70. doi: 10.1128/JVI.02351-14. PMID: 25694591 PMCID: PMC4403472 (IF: 4.606)
17. Vallianou I., Dafou D., **Vassilaki N.**, Mavromara P. and Hadzopoulou-Cladaras M. *Hepatitis C virus suppresses Hepatocyte Nuclear Factor 4 alpha, a key regulator of hepatocellular carcinoma.* **Int J Biochem Cell Biol.** **2016**, 78, 315-26. doi: 10.1016/j.biocel.2016.07.027. PMID: 27477312 (IF: 3.505)
18. Zoidis G., Giannakopoulou E., Stevaert A., Frakolaki E., Myriantopoulos V., Fytas G., Mavromara P., Mikros E., Bartenschlager R., **Vassilaki N.*** and Naesens L.* # *Novel indole-flutimide heterocycles with activity against influenza PA endonuclease and hepatitis C virus.* **Med. Chem. Comm.** **2016**, 7, 447-456. doi: 10.1039/C5MD00439J. (IF: 2.608)
- * **Principal investigators**
Featured as: New Talent Europe (top research from emerging investigators from Europe), 2016 MedChemComm Hot Article (particularly interesting or significant research), Front cover in MedChemComm
19. **Vassilaki N.*** and Frakolaki E. *Virus-host interactions under hypoxia.* Special issue: Effects of hypoxia on infection and host immune control. **Microbes Infect.** **2017**, 19, 193-203. doi: 10.1016/j.micinf.2016.10.004. PMID: 27771294 (IF: 2.924)
- * **Corresponding author**
20. Lougiakis N., Frakolaki E., Karmou P., Pouli N.*, Marakos P., Madan V., Bartenschlager R. and **Vassilaki N.*** *Novel nucleoside analogues targeting HCV replication through an NS5A-dependent inhibition mechanism.* **Chem Biol Drug Des.** **2017**, 90(3), 352-367. doi: 10.1111/cbdd.12966. PMID: 28245093 (IF: 2.328)
- * **Corresponding authors**
21. Ramsis T.M., Abdel Karim S.E., **Vassilaki N.**, Frakolaki E., Kamal A.A.M., Zoidis G., Ahmed N.S. and Abadi A.H. *Expanding the chemical space of anti-HCV NS5A inhibitors by stereochemical exchange and peptidomimetic approaches.* **Arch Pharm (Weinheim).** **2018**, 351(7):e1800017. doi: 10.1002/ardp.201800017. PMID: 29799645 (IF:2.288)
22. Frakolaki E., Kaimou P., Moraiti M., Kalliampakou K. I., Karampetsou K., Dotsika E. Liakos P., Vassilacopoulou D., Mavromara P., Bartenschlager R. and **Vassilaki N.*** *The Role of Tissue Oxygen Tension in Dengue Virus Replication.* **Cells.** **2018**, 7(12), pii: E241. Special Issue Gene Regulation by HIFs during Hypoxia. doi: 10.3390/cells7120241. PMID: 30513781 PMCID: PMC6316080 (IF: 5.656)
- * **Corresponding author**
23. Tsitoura E., Kazazi D., Oz-Arslan D., Sever E. A., Khalili S., **Vassilaki N.**, Aslanoglou E., Dérian N, Six A., Sezerman O. U., Klatzmann D. and Mavromara P. *Comparison of DCs activation by virus-based vaccine delivery vectors emphasises the transcriptional downregulation of the oxidative phosphorylation pathway.* **Hum Gene Ther.** **2019**, 30(4):429-445. doi: 10.1089/hum.2018.161 PMID: 30351174 (IF: 4.241)
24. Vassiliou A.G., Siaterli M.Z., Frakolaki E., Gkogkosi P., Paspaltsis I., Sklaviadis T., Vassilacopoulou D.* and **Vassilaki N.*** *L-Dopa decarboxylase interaction with the major signaling regulator PI3K in*

tissues and cells of neural and peripheral origin. **Biochimie.** **2019**, 160:76-87. doi: 10.1016/j.biochi.2019.02.009. PMID: 30796964 (IF: 3.188)

* **Corresponding authors**

25. Giannakopoulou E., Pardali V., Frakolaki E., Siozos V., Myrianthopoulos V., Mikros E., Taylor M. C., Kelly J. M.*, **Vassilaki N.*** and Zoidis G.* *Scaffold Hybridization Strategy towards potent hydroxamate-based inhibitors of Flaviviridae viruses and Trypanosoma species.* **MedChemComm** **2019**, 10:991-1006. doi: 10.1039/c9md00200f

* **Principal investigators**

26. Leila A., Mousa M., Frakolaki E., **Vassilaki N.**, Bartenschlager R., Zoidis G., Abdel-Halim M. and Abadi A.H. *Symmetric Anti-HCV Agents: Synthesis, Antiviral Properties, and Conformational Aspects of Core Scaffolds.* **ACS Omega** **2019**, 4, 7:11440-11454. doi: 10.1021/acsomega.9b01242

27. Frakolaki E., Kalliampakou K. I., Kaimou P., Moraiti M., Kolaitis N., Boleti H., Koskinas J., Vassilacopoulou D. and **Vassilaki N.*** *Emerging role of L-Dopa decarboxylase in Flaviviridae virus infections.* **Accepted in Cells**

* **Corresponding author**

Published conference proceedings

28. Boumlic A., **Vassilaki N.**, Georgopoulou U., Orfanoudakis G., Mavromara P. *Expression of the ARFP/F/core+1 protein from HCV-1b clinical isolates.* (2006). **Journal of Clinical Virology** 36: S111. (IF:2.630)

Conference: 12th International Symposium on Viral Hepatitis and Liver Disease Location: Paris, France Date: Jul 01-05, 2006

29. **Vassilaki N.**, Friebe P., Paranhos-Baccala G., Mavromara P., Bartenschlager R. *Cis-acting RNA elements within the hepatitis C virus core/core+1 coding region but not core+1 proteins modulate the efficiency of virus proliferation.* (2008). **FEBS J.** 275: 277. (IF: 3.139)

Conference: Joint Conference of the 33rd FEBS Congress/11th IUBMB Location: Athens, Greece Date: Jun 28-Jul 03, 2008

30. Pissas G., Foka PN., **Vassilaki N.**, Kakkanas A., Mavromara P. *Modulation of liver specific gene promoters by the HCV core and core+1/s proteins.* (2008). **FEBS J.** 275: 274. (IF: 3.139)

Conference: Joint Conference of the 33rd FEBS Congress/11th IUBMB Location: Athens, Greece Date: Jun 28-Jul 03, 2008

31. Kalliampakou K., **Vassilaki N.**, Mavromara P. *Translation mediated by the internal ribosome entry site (IRES), of the hepatitis C virus (HCV) genomic RNA, is regulated positively by the phosphorylation of the eukaryotic translation initiation factor 2 alpha (eIF2 alpha).* (2008). **FEBS J.** 275: 270. (IF: 3.139)

Conference: Joint Conference of the 33rd FEBS Congress/11th IUBMB Location: Athens, Greece Date: Jun 28-Jul 03, 2008

32. Dalagiorgou G., **Vasilaki N.**, Kakkanas A., Aslanoglou E., Vassilopoulos D., Hadziyiannis S., Mavromara P. *Detection of humoral responses to the hepatitis C virus core+1 protein in patients with HCV-associated hepatocellular carcinoma.* (2008) **FEBS J.** 275: 268. (IF: 3.139)

Conference: Joint Conference of the 33rd FEBS Congress/11th IUBMB Location: Athens, Greece Date: Jun 28-Jul 03, 2008

33. Boumlic A., Nomine Y., Charbonnier S., Dalagiorgou G., **Vassilaki N.**, Kieffer B., Trave G., Mavromara P., Orfanoudakis G. *Prevalence of intrinsic disorder in the Hepatitis C Virus ARFP/Core+1/S.* (2009) **FEBS J.** 276: 398. (IF: 3.042)
Conference: 34th Congress of the Federation-of-European-Biochemical-Societies Location: Prague, Czech Republic Date: Jul 04-09, 2009
34. Kotta-Loizou I, **Vassilaki N.**, Mavromara P. *Characterization of the translational mechanism that controls the synthesis of HCV core+1/ARF protein.* (2011). **FEBS J.** 278: 87. (IF: 3.790)
Conference: 36th FEBS Congress of the Biochemistry for Tomorrows Medicine Location: Torino, Italy Date: Jun 25-30, 2011.
35. Kotta-Loizou I, **Vassilaki N.**, Mavromara P. *The synthesis of novel HCV core+1/ARF protein as a model system for studying unconventional translation mechanisms.* (2012) **FEBS J.** 279: 507-508. (IF: 4.250)
Conference: 22nd IUBMB Congress/37th FEBS Congress Location: Seville, Spain Date: Sep 04-09, 2012.
36. Vallianou I., **Vassilaki, N.**, Dafou, D., Mavromara P. and Hadzopoulou-Cladaras M. *Hepatitis C virus suppresses HNF4 alpha expression and modulates HNF4 alpha-miR feedback circuit.* (2014) **FEBS J.** 281:471. (IF: 4.001)
Conference: FEBS EMBO 2014, Location: Paris, France, Date: Aug 30-SEP 04, 2014

Patents

1. Mavromara P. and **Vassilaki N.** "Novel HCV core+1 protein, methods for diagnosis of HCV infections, prophylaxis and for screening of anti-HCV agents, nucleic acids and new polypeptides associated with and/or overlapping with HCV core gene products"
U.S. Patent Office, Patent No. US 7,838,002 B2, Application No. 11/322,374, Issue date 23/11/2010
2. Mavromara P. and **Vassilaki N.** "*In vitro* expression of the HCV ARFP/F/CORE+1 coding open reading frame"
U.S. Provisional Patent Application No. 60/614,610

PRESENTATIONS IN CONFERENCES

1. **26th International Symposium on Hepatitis C Virus and Related Viruses.** Seoul, South Korea, 5-8 Oct. 2019
Oral Presentation: Role of hypoxia in Flaviviridae viruses replication and inhibition by antiviral drugs
Frakolaki E., Kalliampakou K.I., Chalari A., Zoidis G., Windisch M., Bartenschlager R. and **Vassilaki N.**
2. **26th International Symposium on Hepatitis C Virus and Related Viruses.** Seoul, South Korea, 5-8 Oct. 2019
Poster Presentation: Emerging role of L-dopa decarboxylase in DENV and HCV infection
Frakolaki E., Kalliampakou K.I., Chalari A., Siozos V., Boleti H. Koskinas J., Vassilacopoulou D. and **Vassilaki N.**
3. **Natural Products in Drug Discovery and Human Health (NatProdDDH) – PSE Meeting.** Lisbon, Portugal, 28-31 July 2019
Poster Presentation: Evaluation of antioxidant activity, total phenolic content and hepatotoxicity of herbal infusions

- Sotiropoulou N. S., Frakolaki E., **Vassilaki N.** and Tarantilis P.
4. **11th Joint Meeting on Medicinal Chemistry (JMMC) 2019.** Prague, Czech Republic, 27-30 June 2019
Poster Presentation (Best Poster award, selected for Oral Presentation): Metal-chelating agents with improved inhibitory activity against Hepatitis C Virus
Giannakopoulou E., Pardali V., Frakolaki E., Myrianthopoulos V., Mikros E., Bartenschlager R., **Vassilaki N.** and Zoidis G.
 5. **EFMC-ACSMEDI MedChem Frontiers 2019.** Krakow, Poland 10-13 June 2019
Poster Presentation: Metal-Chelating agents with dual inhibitory activity against Hepatitis C and Dengue viruses
Giannakopoulou E., Pardali V., Frakolaki E., Myrianthopoulos V., Mikros E., Bartenschlager R., **Vassilaki N.** and Zoidis G.
 6. **32nd International Conference on Antiviral Research (ICAR),** hosted by the International Society for Antiviral Research (ISAR). Baltimore, USA. 12-15 May 2019
Poster Presentation: Metal chelating agents with improved inhibitory activity against hepatitis C virus
Giannakopoulou E., Pardali V., Frakolaki E., Myrianthopoulos V., Mikros E., Bartenschlager R., **Vassilaki N.** and Zoidis G.
 7. **17th Panhellenic Hepatology Congress.** Kalamata, Greece. 9-11 May 2019
Oral Presentation: Role of a catecholamine biosynthetic enzyme in Hepatitis C virus infection and the development of hepatocellular carcinoma mediated by the PI3K/AKT pathway
Frakolaki E., Kaimou P., Moraiti M., Boleti H. Koskinas J., Bartenschlager R., Vassilacopoulou D. and **Vassilaki N.**
 8. **26th Two-day Conference dedicated to Viral Hepatitis B and C "Hadziyannis S".** Athens, Greece. 26-27 Jan. 2019
Oral Presentation: Association of a novel PI3K-binding partner with Hepatitis C virus infection and the development of hepatocellular carcinoma
Frakolaki E., Kaimou P., Moraiti M., Boleti H. Koskinas J., Bartenschlager R., Vassilacopoulou D. and **Vassilaki N.**
 9. **25th International Symposium on Hepatitis C Virus and Related Viruses.** Dublin, Ireland, 8-11 Oct. 2018
Poster Presentation: Novel acetohydroxamic metal-chelators targeting the replication of *Flaviviridae* viruses.
Frakolaki E., Niotis G., Karakostas C., Giannakopoulou E., Pardali V., Windisch M., Bartenschlager R., Papageorgiou N., Canard B., Zoidis G. and **N. Vassilaki.**
 10. **XXV EFMC International Symposium on Medicinal Chemistry (EFMC-ISMC 2018).** Ljubljana, Slovenia, 2-6 Sep. 2018
Poster Presentation: Metal-Chelating Acetohydroxamic Acids against Hepatitis C Virus and Flaviviruses
Giannakopoulou E., Pardali V., Frakolaki E., Myrianthopoulos V., Mikros E., Bartenschlager R., **Vassilaki N.** and Zoidis G.
 11. **XXV EFMC International Symposium on Medicinal Chemistry (EFMC-ISMC 2018).** Ljubljana, Slovenia, 2-6 Sep. 2018
Poster Presentation (selected for a shotgun oral presentation): Novel Hydantoin-based Acetohydroxamic Acid Derivatives, as Metal Chelating Agents with Dual-Targeting Function against *T. brucei* and Hepatitis C Virus

- Pardali V., Giannakopoulou E., Frakolaki E., Taylor M. C., Myrianthopoulos V., Mikros E., Bartenschlager R., **Vassilaki N.**, Kelly J.M. and Zoidis G.
12. **5th EFMC Young Medicinal Chemistry Symposium (EFMC-YMCS 2018)**. Ljubljana, Slovenia, 2-6 Sep. 2018
Poster Presentation: *N*-Acetohydroxamic Acid Derivatives and *N*-Hydroxyimides as Metal-Chelating Agents against Viral and Parasitic Diseases
Pardali V., Giannakopoulou E., Edwards T.C., Meyers M. J., Frakolaki E., Stevaert A., Taylor M. C., Myrianthopoulos V., Mikros E., Bartenschlager R., **Vassilaki N.**, Naesens L., Kelly J. M., Tavis J. E. and Zoidis G.
 13. **31st International Conference on Antiviral Research (ICAR)**. Porto, Portugal, 11-15 June 2018
Poster Presentation: Acetohydroxamic Metal-Chelators against Hepatitis C Virus and Flaviviruses
Giannakopoulou E., Pardali V., Frakolaki E., Myrianthopoulos V., Mikros E., Bartenschlager R., **Vassilaki N.** and Zoidis G.
 14. **31st International Conference on Antiviral Research (ICAR)**. Porto, Portugal, 11-15 June 2018.
Poster Presentation: Metal Chelating Agents against Viruses
Zoidis G., Giannakopoulou E., Pardali V., Edwards T.C., Frakolaki E., Myrianthopoulos V., Mikros E., Bartenschlager R., **Vassilaki N.** and Tavis J.
 15. **4th Meeting of Postgraduate and Postdoctoral Researchers of Hellenic Pasteur Institute**. Athens, Greece, 27 Sep. 2018
Oral Presentation (received Best Oral Presentation Award): Interaction between tissue normoxia and Dengue Virus replication.
Moraiti M., Frakolaki E., Kolaitis N., Kaimou P., Kalliampakou A., Karampetsou K., Dotsika E., Vassilacopoulou D., Mavromara P., Bartenschlager R. and **Vassilaki N.**
 16. **68th Congress of the Hellenic Society of Biochemistry and Molecular Biology**. Athens, Greece, 10-12 Nov. 2017
Oral Presentation: Developing a novel infectious cell model of *Flaviviridae* viruses that simulates in vivo normoxic and metabolic microenvironment for the characterization of broadly effective antivirals
Frakolaki E., Kaimou P., Niotis G., Dimitriou M., Giannakopoulou E., Pardali V., Myrianthopoulos V., Mikros E., Bartenschlager R., Mavromara P., Zoidis G. and **Vassilaki N.**
 17. **24th International Symposium on Hepatitis C Virus and Related Viruses**. Cape Cod, Massachusetts, USA, 25-28 Sep. 2017
Poster Presentation: Broadly Active Chelating Inhibitors of Flaviviridae Viruses. Characterization under Tissue Normoxic Conditions that Favor Viral Replication
Frakolaki E., Giannakopoulou E., Pardali V., Myrianthopoulos V., Dimitriou M., Niotis G., Mikros E., Windisch M., Bartenschlager R., Zoidis G. and **Vassilaki N.**
 18. **10th Joint Meeting on Medicinal Chemistry (10th JMMC)**. Dubrovnik, Croatia. 25-28 June 2017
Poster Presentation: Broadly effective metal chelators, as influenza PA endonuclease and hepatitis C virus inhibitors
Giannakopoulou E., Stevaert A., Frakolaki E., Myrianthopoulos V., Mikros E., Bartenschlager R., **Vassilaki N.**, Naesens L. and Zoidis G.
 19. **17th Hellenic Symposium on Medicinal Chemistry (17th HSMC)**. Thessaloniki, Greece. 01-03 June 2017
Poster Presentation (Best poster award): Broadly effective metal chelators, as influenza PA endonuclease and hepatitis c virus inhibitors
Giannakopoulou E., Stevaert A., Frakolaki E., Myrianthopoulos V., Mikros E., Bartenschlager R., **Vassilaki N.**, Naesens L. and Zoidis G.

20. **67th Panhellenic Conference of the Hellenic Society of Biochemistry and Molecular Biology.** Ioannina, Greece, 25-27 Nov. 2016
Oral Presentation: Mechanism of action of broadly effective inhibitors targeting hepaci- and flavivirus replication: Validation under liver normoxic conditions
 Frakolaki E., Kaimou P., Kelepouras K., Giannakopoulou E., Myrianthopoulos V., Niotis G., Mikros E., Bartenschlager R., Mavromara P., Zoidis G. and **Vassilaki N.**
21. **Institut Pasteur International Network Symposium 2016, "From basic science to biomarkers and tools in Global Health".** Paris, France, 29 Nov. - 2 Dec., 2016
Poster Presentation: The interplay between Flaviviridae viruses and hepatic normoxia determines viral replication levels and response to therapeutics
 Frakolaki E., Giannakopoulou E., Bartenschlager R., Mavromara P., Zoidis G. and **Vassilaki N.**
22. **23rd International Symposium on Hepatitis C Virus and Related Viruses.** Kyoto, Japan, 11-15 Oct. 2016
Poster Presentation: Broadly active antivirals with a naturally derived chelating moiety targeting hepaci- and flavivirus replication; further evaluation under liver normoxic conditions
 Frakolaki E., Giannakopoulou E., Myrianthopoulos V., Dimitriou M., Madan V., Mikros E., Bartenschlager R., Mavromara P., Zoidis G. and **Vassilaki N.**
23. **XXIV EFMC International Symposium on Medicinal Chemistry (ISMC).** Manchester, UK, 28 Aug. - 1 Sep. 2016
Poster Presentation: Novel indole-flutimide heterocycles with activity against influenza PA endonuclease and Hepatitis C virus.
 Zoidis G., Giannakopoulou E., Stevaert A., Frakolaki E., Myrianthopoulos V., Fytas G., Mavromara P., Mikros E., Bartenschlager R., **Vassilaki N.** and Naesens L.
24. **2nd International Congress of Greek Local Chapter of CRS (Controlled Release Society):** From Medicinal Chemistry - Natural Products to Pharmaceuticals & Pharmacokinetics / Pharmacodynamics. Athens, Greece, Aegli Zappiou, 22-24 June 2016.
Poster Presentation: Novel indole-flutimide heterocycles with activity against influenza PA endonuclease and Hepatitis C virus.
 Giannakopoulou E., Stevaert A., Frakolaki E., Myrianthopoulos V., Mikros E., **Vassilaki N.**, Bartenschlager R., Naesens L. and Zoidis G.
25. **29th International Conference on Antiviral Research (ICAR).** La Jolla, California, United States, 17- 21 April 2016
Poster Presentation: Novel indole-flutimide Heterocycles with Activity Against Influenza PA Endonuclease and Hepatitis C Virus.
 Zoidis G., Giannakopoulou E., Myrianthopoulos V., Fytas G., Mikros E., Stevaert A., Naesens L., Frakolaki E., Mavromara P., **Vassilaki N.** and Bartenschlager R.
26. **66th Congress of the Hellenic Society of Biochemistry and Molecular Biology.** Eugenides Foundation, Athens, Greece, 11-13 Dec. 2015
Oral Presentation: Developing a novel infectious cell culture system of Hepatitis C virus that simulates liver normoxia for the characterization of broadly effective inhibitors targeting the viral polymerase.
 Frakolaki E., Giannakopoulou E., Myrianthopoulos V., Dimitriou M., Madan V., Bartenschlager R., Mavromara P., Zoidis G. and **Vassilaki N.**
27. **Scientific Symposium of the Institut Pasteur International Network 2015.** Paris, France, 14-16 Oct. 2015
Poster Presentation: Action and resistance mechanism in hepatotropic virus replication of broadly effective antivirals with a naturally derived chelating moiety. The interplay between virus and liver

normoxia as a possible determinant of virus susceptibility

Frakolaki E., Giannakopoulou E., Myriantopoulos V., Dimitriou M., Madan V., Mikros E., Windisch M., Bartenschlager R., Mavromara P., Zoidis G. and **Vassilaki N.**

28. **22nd International Symposium on Hepatitis C Virus and Related Viruses.** Strasbourg, France, 9-13 Oct. 2015

Poster Presentation: Broadly active antiviral drugs with a naturally derived chelating moiety targeting Hepatitis C Virus replication

Frakolaki E., Giannakopoulou E., Myriantopoulos V., Dimitriou M., Madan V., Mikros E., Windisch M., Bartenschlager R., Mavromara P., Zoidis G. and **Vassilaki N.**

29. **22nd International Symposium on Hepatitis C Virus and Related Viruses.** Strasbourg, France, 9-13 Oct. 2015

Poster Presentation: Expression and functional properties of the short Core+1/ARF protein in the HCV life cycle

Vassilaki N., Frakolaki E., Kazazi D., Karakasiliotis I., Moustafa S., Bartenschlager R. and Mavromara P.

30. **1st Meeting of Postgraduate and Postdoctoral Researchers of Hellenic Pasteur Institute.** Athens, Greece, 24 Sep. 2015

Oral Presentation: Broadly effective antiviral drugs with a naturally derived chelating group against Hepatitis C Virus replication

Frakolaki E., Giannakopoulou E., Myriantopoulos V., Dimitriou M., Madan V., Mikros E., Windisch M., Bartenschlager R., Mavromara P., Zoidis G. and **Vassilaki N.**

31. **Keystone Symposia on Molecular and Cellular Biology. Viruses and Human Cancer.** Big Sky, Montana, USA, 29 March-3 April, 2015

Poster Presentation: Expression and function of a unique HCV protein, known as core+1/ARFP protein

Karakasiliotis I., Kotta-Loizou I., Vassilaki N., Frakolaki E., Kassela K., Moustafa S., Kazazi D, Kakkanas A., Bartenschlager R. and Mavromara P.

32. **10th Conference of the Hellenic Society of Virology.** Athens, Greece, 27-28 Feb. 2015

Poster Presentation: Identifying new antivirals from natural products: The example of flutimide as an HCV replication inhibitor

Frakolaki E., Giannakopoulou E., Myriantopoulos V., Madan V., Mikros E., Bartenschlager R., Mavromara P., Zoidis G. and **Vassilaki N.**

33. **10th Conference of the Hellenic Society of Virology.** Athens, Greece, 27-28 Feb. 2015

Oral Presentation: Phenotypic evaluation of mutations that disrupt the core+1 ORF or alter the core aminoacid sequence of Hepatitis C Virus

Vassilaki N., Frakolaki E., Samaras A., M. Dimitriou, Kotta-Loizou I., Karakasiliotis I., Bartenschlager R. and Mavromara P.

34. **10th Conference of the Hellenic Society of Virology.** Athens, Greece, 27-28 Feb. 2015

Poster Presentation: Expression of the alternative core+1/ARF protein of Hepatitis C Virus during viral replication

Karakasiliotis I., Kotta-Loizou I., Vassilaki N., Sakellariou P., Moustafa S., Frakolaki E., Kassela K, Bartenschlager R. and Mavromara P.

35. **Scientific Symposium of the Institut Pasteur International Network 2014.** Paris, 10-13 Sep. 2014

36. **21st International Symposium on Hepatitis C Virus and Related Viruses.** Banff, Canada, 7-11 Sep. 2014

Poster Presentation: Derivatives of the fungal metabolite flutimide as novel HCV replication inhibitors

Frakolaki E., Giannakopoulou E., Myriantopoulos V., Madan V., Mikros E., Bartenschlager R.,

- Mavromara P., Zoidis G. and **Vassilaki N.**
37. **Scientific Symposium of the Institut Pasteur International Network 2014.** Paris, 10-13 Sep. 2014
38. **21st International Symposium on Hepatitis C Virus and Related Viruses.** Banff, Canada, 7-11 Sep. 2014
Poster Presentation: Mutations introducing stop codons in HCV core+1 ORF and a single aminoacid substitution in core which is present in clinical isolates impair viral infectivity
Vassilaki N., Frakolaki E., Samaras A., Kotta-Loizou I., Karakasiliotis I., Bartenschlager R. and Mavromara P.
39. **21st International Symposium on Hepatitis C Virus and Related Viruses.** Banff, Canada, 7-11 Sep. 2014
Poster Presentation: Expression of the unique HCV core+1/ARF protein in the context of JFH1-based replicons
Karakasiliotis I., Kotta-Loizou I., Vassilaki N., Sakellariou P., Moustafa S., Frakolaki E., Kassela K, Bartenschlager R. and Mavromara P.
40. **64th Congress of the Hellenic Society of Biochemistry and Molecular Biology.** Evgenides Foundation, Athens, Greece, 6-8 Dec. 2013
Oral Presentation: An IRES-like element identified within the HCV core-coding region mediates internal translation initiation of the core+1/Short protein in the HCV replicon.
Vassilaki N., Kotta-Loizou I., Sakellariou P., Frakolaki E., Bartenschlager R. and Mavromara P.
41. **20th International Symposium on Hepatitis C Virus and Related Viruses.** Melbourne, Australia, 6-10 Oct. 2013
Poster Presentation: Two isoforms of HCV core+1/ARFP protein are expressed in the context of the HCV replicon system through alternative translation mechanisms.
Vassilaki N., Kotta-Loizou I., Sakellariou P., Bartenschlager R. and Mavromara P.
42. **Eurovirology 2013: 5th European Congress of Virology.** Lyon, FRANCE, 11-14 Sep. 2013
Poster Presentation: Characterization of the translational mechanism that controls the synthesis of the short form of HCV Core+1/ARFP protein
Vassilaki N., Kotta-Loizou I., Sakellariou P., Bartenschlager R. and Mavromara P.
43. **EMBO Workshop on Liver and Pancreas Development, Function and Disease.** Cape Sounio, Athens, Greece, 26-30 May 2013
Poster Presentation: Hepatitis C virus modulates the expression of HNF4 α , the master transcription factor of host lipid metabolism
Vallianou I., **Vassilaki N.,** Dafou D., Kakkanas A., Mavromara P., Hadzopoulou-Cladaras M.
44. **63rd Conference of the Hellenic Society for Biochemistry and Molecular Biology (HSBMB).** Crete, Greece, 9-11 Nov. 2012.
Poster Presentation: Low Oxygen Tension Enhances Hepatitis C Virus Replication.
Vassilaki N., Kalliampakou K.I., Kotta-Loizou I., Befani C., Liakos P., Simos G., Mentis A.F., Kalliaropoulos A., Doumba P.P., Smirlis D., Bauhofer O., Poenisch M., Windisch M.P., Lee M.E., Koskinas J., Bartenschlager R. and Mavromara P.
45. **19th International Symposium on Hepatitis C Virus and Related Viruses.** Venice, Italy, 5-9 Oct. 2012
Poster Presentation: Hepatitis C virus replication induction under low O₂ in Huh7 cells correlates with upregulation of oncogene and creatine kinase B mediated metabolism.
Vassilaki N., Kalliampakou K.I., Kotta-Loizou I., Befani C., Liakos P., Simos G., Mentis A. F., Kalliaropoulos A., Doumba P.P., Smirlis D., Bauhofer O., Poenisch M., Windisch M.P., Lee M., Koskinas J., Bartenschlager R. and Mavromara P.
46. **19th International Symposium on Hepatitis C Virus and Related Viruses.** Venice, Italy, 5-9 Oct. 2012
Poster Presentation: Two isoforms of HCV core+1/ARF protein are expressed in the context of the HCV replicon system.

- Kotta-Loizou I., **Vassilaki N.**, Bartenschlager R. and Mavromara P.
47. **19th International Symposium on Hepatitis C Virus and Related Viruses.** Venice, Italy, 5-9 Oct. 2012
Poster Presentation: The novel HCV core+1/ARF protein represses hepcidin promoter activity through transcription factor activator protein-1 in hepatoma cells.
- Kotta-Loizou I., **Vassilaki N.**, Bartenschlager R. and Mavromara P.
48. **22nd IUMBM and 37th FEBS Congress.** Seville, Spain, 4-9 Sep. 2012
Poster Presentation: The synthesis of novel HCV core+1/ARF protein as a model system for studying unconventional translation mechanisms.
- Kotta-Loizou I., **Vassilaki N.** and Mavromara P.
49. **62nd Conference of the Hellenic Society for Biochemistry and Molecular Biology (HSBMB).** Athens, Greece, 9-11 Dec. 2011.
Poster Presentation: Low Oxygen Tension Enhances Hepatitis C Virus Replication in Correlation with Changes in Cell Bioenergetics.
- Vassilaki N.**, Kalliampakou K.I., Kotta-Loizou I., Befani C., Liakos P., Simos G., Smirlis D., Bauhofer O., Poenisch M., Windisch M.P., Lee M., Bartenschlager R. and Mavromara P.
50. **62nd Conference of the Hellenic Society for Biochemistry and Molecular Biology (HSBMB).** Athens, Greece, 9-11 Dec. 2011.
Poster Presentation: The novel HCV core+1/ARF protein modulates hepcidin promoter activity in hepatoma cells.
- Kotta-Loizou I., **Vassilaki N.**, Pissas G., Simos G. and Mavromara P.
51. **62nd Conference of the Hellenic Society for Biochemistry and Molecular Biology (HSBMB).** Athens, Greece, 9-11 Dec. 2011.
Poster Presentation: Evidence towards a novel translational mechanism involved in the HCV core+1/ARF protein synthesis.
- Kotta-Loizou I., **Vassilaki N.** and Mavromara P.
52. **18th International Symposium on Hepatitis C Virus and Related Viruses.** Seattle, Washington, USA, 8-12 Sep. 2011.
Poster Presentation: Hepatitis C virus replication enhancement at low oxygen tension is associated with higher anaerobic energy metabolism in hepatoma cells.
- Vassilaki N.**, Kalliampakou K.I., Kotta-Loizou I., Befani C., Liakos P., Simos G., Smirlis D., Bauhofer O., Poenisch M., Windisch M. P., Lee M., Bartenschlager R. and Mavromara P.
53. **18th International Symposium on Hepatitis C Virus and Related Viruses.** Seattle, Washington, USA, 8-12 Sep. 2011.
Poster Presentation: Expression of the HCV core+1/ARF protein in the context of the HCV replicon system.
- Kotta-Loizou I., **Vassilaki N.** and Mavromara P.
54. **36th FEBS Congress “Biochemistry for tomorrow’s medicine”.** Torino, Italy, 25-30 June 2011.
Poster Presentation: Characterization of the translational mechanism that controls the synthesis of HCV core+1/ARF protein.
- Kotta-Loizou I., **Vassilaki N.** and Mavromara P.
55. **36th FEBS Congress “Biochemistry for tomorrow’s medicine”.** Torino, Italy, 25-30 June 2011.
Poster Presentation: Low oxygen tension causes enhancement of Hepatitis C virus replication in hepatoma cells which is associated with an increase in intracellular ATP levels.
- Vassilaki N.**, Kalliampakou K.I., Kotta-Loizou I., Befani C., Liakos P., Simos G., Smirlis D., Windisch M.P., Lee M.E., R. Bartenschlager R. and Mavromara P.

56. **61st Conference of the Hellenic Society for Biochemistry and Molecular Biology (HSBMB).** Alexandroupoli, Greece, 15-17 Oct. 2010.
Poster Presentation: Functional properties of the novel HCV core+1 protein: down-regulation of hepcidin promoter activity in hepatic cell lines.
 Kotta-Loizou I., **Vassilaki N.**, Pissas G., Simos G. and Mavromara P.
57. **17th International Symposium on Hepatitis C Virus and Related Viruses.** Yokohama, Japan, 10-14 Sep. 2010.
Poster Presentation: Low oxygen enhances hepatitis C virus replication in a HIF-1 α and HIF-2 α independent manner in cultured hepatocytes.
Vassilaki N., Kalliampakou K.I., Kotta-Loizou I., Simos G., Liakos P., Smirlis D., Befani C., Bartenschlager R. and Mavromara P.
58. **Final annual DC-THERA network meeting.** Athens, May 2010
 Dendritic cell signatures of virus-based vaccine delivery vehicles.
 Kazazi D., Tsitoura E., Khalili S., Oz-Arslan D., **Vassilaki N.**, Aslanoglou E., Kochlios M., Beltrame L., Cavalieri D., Benes V., Brocker T., Klatzmann D. and Mavromara P.
59. **4th European Congress of Virology.** Lake Como, Italy, 7-11 Apr. 2010.
Oral and poster Presentations: Oxygen tension modulates hepatitis C virus proliferation.
Vassilaki N., Kalliampakou K.I., Kotta-Loizou I., Smirlis D., Bartenschlager R. and Mavromara P.
60. **60th Conference of the Hellenic Society for Biochemistry and Molecular Biology (HSBMB).** Athens, Greece, 20-22 Nov. 2009.
Poster Presentation: Hepatitis C virus proliferation in cultured cells is favored at low oxygen tensions present in the human liver tissue.
Vassilaki N., Kalliampakou K. I., Kotta-Loizou I., Smirlis D., Bartenschlager R. and Mavromara P.
61. **60th Conference of the Hellenic Society for Biochemistry and Molecular Biology (HSBMB).** Athens, Greece, 20-22 Nov. 2009.
Poster Presentation: High levels of HCV core+1 antibodies in HCV patients with hepatocellular carcinoma
 Dalagiorgou G., **Vassilaki N.**, Foka P., Boumlic A., Khalili S., Kakkanas A., Veletza S., Vassilopoulos D., Hatziyiannis J., Koskinas J. and Mavromara P.
62. **60th Conference of the Hellenic Society for Biochemistry and Molecular Biology (HSBMB).** Athens, Greece, 20-22 Nov. 2009.
Poster Presentation: Gene expression profiling of dendritic cells upon in vivo exposure to candidate vaccine vectors.
 Tsitoura E., Kazazi D., **Vassilaki N.**, Aslanoglou E., Kochlios M., Khalili S., Oz-Arslan D., Kreppel F., Kochanek S., Jennings G., Cosset F., Epstein A., Dalianis T., Williamson A., Bellier B., Brocker T., Ivacevic T., Benes V., Klatzmann D. and Mavromara P.
63. **16th International Symposium on Hepatitis C Virus and Related Viruses.** Nice, France, 3-7 Oct. 2009.
Poster Presentation: Lower oxygen tensions induce hepatitis C virus replication in cultured hepatocytes.
Vassilaki N., Kalliampakou K. I., Kotta-Loizou I., Bartenschlager R. and Mavromara P.
64. **16th International Symposium on Hepatitis C Virus and Related Viruses.** Nice, France, 3-7 Oct. 2009.
Poster Presentation: Higher levels of HCV core+1 antibodies in patients with HCV-associated hepatocellular carcinoma in comparison to chronically infected patients.
 Dalagiorgou G., **Vassilaki N.**, Boumlic A., Khalili S., Kakkanas A., Foka P., Aslanoglou E., Veletza S., Vassilopoulos D., Hatziyiannis J., Koskkinas J. and Mavromara P.

65. **16th International Symposium on Hepatitis C Virus and Related Viruses.** Nice, France, 3-7 Oct. 2009.
Poster Presentation: Unusual serological profile of core/ARFP antibodies: New insights into the production of the ARF/core+1 protein *in vivo*.
Budkowska A., Kakkanas T., Nerrinet E., Kalinina O., Maillard P., Horm S., Dalagiorgou G., Vassilaki N., Georgopoulou U. and Mavromara P.
66. **5th International Greek Biotechnology Forum.** Athens, Greece, 8-9 May, 2009.
Gene Expression Profiling of Dendritic Cells upon *In Vivo* Exposure to Candidate Vaccine Vectors.
Kazazi D. Tsitoura E., Vassilaki N., Aslanoglou E., Kochlios M. , Khalili S. , Oz-Arslan D. Kreppel F., Kochanek S., Gennings G., Cosset F., Epstein A., Dalianis T., Williamson A., Bellier B., Six A. Brocker T., Ivacevic T., Benes V., Klatzmann D., Mavromara P.
67. **15th International Symposium on Hepatitis C Virus and Related Viruses.** San Antonio, Texas, 5-9 Oct. 2008.
Oral Presentation: Cell culture and *in vivo* studies on the importance of hepatitis C virus core RNA structure integrity and core+1 reading frame expression for viral RNA translation and replication.
Vassilaki N., Friebe P., Meuleman P., Kaul A., Kallis S., Leroux-Roels G., Mavromara P. and Bartenschlager R.
68. **15th International Symposium on Hepatitis C Virus and Related Viruses.** San Antonio, Texas, 5-9 Oct. 2008.
Poster Presentation: Role of hepatitis C virus core+1 reading frame proteins expressed in human hepatoma cells on viral proliferation and cellular gene expression.
Vassilaki N., Kazazi D., Tsitoura E., Paranhos-Baccala G., Bartenschlager R. and Mavromara P.
69. **International Congress of Virology IUMS 2008.** Istanbul, Turkey, 10-15 Aug. 2008
Poster Presentation: Exploring the importance of the hepatitis C virus core RNA secondary structure and core+1 reading frame expression for viral RNA translation and replication.
Vassilaki N., Friebe P., Paranhos-Baccalà G., Mavromara P. and Bartenschlager R.
70. **33rd FEBS Congress and 11th IUBMB Conference.** Athens, Greece, 28 June-3 July 2008
Poster Presentation: Cis-acting RNA elements within the hepatitis C virus core/core+1 coding region but not core+1 proteins modulate the efficiency of virus proliferation.
Vassilaki N., Friebe P., Paranhos-Baccalà G., Mavromara P. and Bartenschlager R.
71. **33rd FEBS Congress and 11th IUBMB Conference.** Athens, Greece, 28 June-3 July 2008
Poster Presentation: Translation mediated by the internal ribosome entry site (IRES), of the hepatitis C virus (HCV) genomic RNA, is regulated positively by the phosphorylation of the eukaryotic translation initiation factor 2 α (eIf2 α).
Kalliampakou K., Vassilaki N. and P. Mavromara
72. **33rd FEBS Congress and 11th IUBMB Conference.** Athens, Greece, 28 June-3 July 2008
Poster Presentation: Detection of humoral responses to the hepatitis C virus core+1 protein in patients with HCV-associated hepatocellular carcinoma.
Dalagiorgou G., Vassilaki N., Kakkanas A., Aslanoglou E., Vassilopoulos D., Hadziyannis St. and P. Mavromara
73. **33rd FEBS Congress and 11th IUBMB Conference.** Athens, Greece, 28 June-3 July 2008
Poster Presentation: Modulation of liver specific gene promoters by the HCV core and core+1/S proteins.
Pissas G., Foka P., Vassilaki N. Kakkanas A. and Mavromara P.
74. **Conference Scientifique Internationale du Reseau International des Instituts Pasteur.** IP Paris, France, 26-27 June 2008
Biological role of a novel protein (core+1/F) encoded by the alternative open reading frame of the

hepatitis C virus genome.

Budkowska A., Kakkanas T., Nerrienet E., Kalinina O., Maillard P., Sorn V., Dalagiorgou G., Vassilaki N. and Mavromara P.

75. **18th GFV Annual Meeting.** Heidelberg, Germany, 5-8 March 2008

Poster Presentation: Role of the hepatitis C virus core+1 open reading frame and cis-acting RNA elements in viral replication and translation.

Vassilaki N., Friebe P., Paranhos-Baccala G., Mavromara P and Bartenshlager R.

76. **59th Conference of the Hellenic Society for Biochemistry and Molecular Biology (HSBMB).** Athens, Greece, 7-9 Dec. 2007.

Oral Presentation : Role of hepatitis C virus core+1 open reading frame and core cis-acting RNA elements in viral translation and replication.

Vassilaki N., Friebe P., Paranhos-Baccala G., Mavromara P. and Bartenschlager R.

77. **59th Conference of the Hellenic Society for Biochemistry and Molecular Biology (HSBMB).** Athens, Greece, 7-9 Dec. 2007.

Poster Presentation : Effect of the novel HCV core+1/S protein on liver specific gene promoters.

Pissas G., Foka P., Vassilaki N. and Mavromara P.

78. **59th Conference of the Hellenic Society for Biochemistry and Molecular Biology (HSBMB).** Athens, Greece, 7-9 Dec. 2007.

Poster Presentation : The use of home made ELISA and immunoblotting assays for the detection of antibodies in sera of HCV infected patients.

Kakkanas A., Dalagiorgou G., Vassilaki N., Khalili S., Aslanoglou E., Tsitoura P., Georgopoulou U., Mavromara P., Budkowska A., Maillard P., Kalinina O., Nerrienet E. and Viseth

79. **14th International Symposium on Hepatitis C Virus and Related Viruses.** Glasgow, Scotland, 9-13 Sept. 2007.

Poster Presentation : Role of hepatitis C virus core+1 open reading frame and cis-acting RNA elements in viral replication.

Vassilaki N., Friebe P., Paranhos-Baccalà G., Mavromara P. and Bartenschlager R.

80. **14th International Symposium on Hepatitis C Virus and Related Viruses.** Glasgow, Scotland, 9-13 Sept. 2007.

Poster Presentation : Expression of alternative proteins from the core coding region derived from HCV-1b subtype HCC associated clinical isolates.

Boumlic A., Vassilaki N., Georgopoulou U., Orfanoudakis G., Mavromara P.

81. **12th International Symposium of Viral Hepatitis and Liver Disease.** Paris, France, 1-5 July 2006.

Poster Presentation : Expression of the ARFP/F/core+1 protein from HCV-1b clinical isolates.

Boumlic A., Vassilaki N., Georgopoulou U., Orfanoudakis G. and Mavromara P.

82. **12th International Symposium on Hepatitis C Virus and Related Viruses.** Montreal, Canada, 2-6 Oct. 2005.

Poster Presentation : Enhancement of the -2/+1 and -1/+2 translational frameshifting events within the HCV core coding sequences in a mammalian cytoplasmic expression system.

Vassilaki N. and Mavromara P.

83. **31st Annual Panhellenic Medical Congress.** Athens, Greece, 17-21 May, 2005.

Oral Presentation : Investigation of the biological importance of the newly discovered core+1 protein of the hepatitis C virus.

Vassilaki N., Shirin Khalili and Mavromara P.

84. **27th Annual Scientific Conference of the Hellenic Society for Biological Sciences.** Nafplio, Greece, 12-14 May, 2005.

Poster Presentation : Characterization of the expression and function of the newly discovered core+1

protein of the hepatitis C virus.

Vassilaki N. and Mavromara P.

85. **11th International Symposium on Hepatitis C Virus and Related Viruses. Molecular Virology, Pathogenesis and Antiviral Therapy.** Heidelberg, Germany, 3-7 Oct. 2004.

Oral Presentation : Expression studies on the short form of the HCV ARFP/F/core+1 protein in mammalian cells.

Vassilaki N. and Mavromara P.

86. **26th Annual Scientific Conference of the Hellenic Society for Biological Sciences.** Volos, Greece, 27-30 May, 2004.

Poster Presentation : Studies on the mechanisms responsible for the translation of the HCV ARFP/F/core+1 coding ORF *in vitro* and in mammalian cells.

Vassilaki N. and Mavromara P.

87. **10th International Meeting on Hepatitis C Virus and Related Viruses. Molecular Virology and Pathogenesis.** Kyoto, Japan, 2-6 Dec. 2003.

Poster Presentation : Two alternative translation mechanisms operate within the HCV open reading frame that encodes the ARFP/F/core+1 protein in transfected cells.

Vassilaki N. and Mavromara P.

88. **55th Conference of the Hellenic Society for Biochemistry and Molecular Biology (HSBMB).** Foundation for Biomedical Research of the Academy of Athens, Athens, Greece, 13-15 Nov. 2003.

Poster Presentation : An internal translation initiation mechanism directs the synthesis of a shorter form of the novel HCV ARFP/F/core+1 protein

Vassilaki N. and Mavromara P.

89. **25th Annual Scientific Conference of the Hellenic Society for Biological Sciences.** Mytilini, Greece, 29 May -1 June, 2003.

Oral Presentation : An alternative translation mechanism is implicated in the production of the HCV ARFP/F/core+1 protein in transfected mammalian cells.

Vassilaki N. and Mavromara P.

90. **24th Annual Scientific Conference of the Hellenic Society for Biological Sciences.** Eretria, Euboea island, Greece, 23-26 May, 2002.

Oral Presentation : Evidence for the presence of a novel ribosomal frameshifting mechanism within the core coding region of the Hepatitis C Virus.

Vassilaki N. and Mavromara P.

91. **8th International Symposium on Hepatitis C Virus & Related Viruses. Molecular Virology and Pathogenesis.** Paris, France, 2-5 Sep. 2001.

Poster Presentation : Evidence for the presence of ribosomal +1/-1 frameshifting mechanism(s) within the core coding region of the Hepatitis C Virus.

Vassilaki N., Varaklioti R., Georgopoulou U. and Mavromara P.

92. **7th International Meeting on Hepatitis C Virus and Related Viruses. Molecular Virology and Pathogenesis.** Gold coast, Queensland, Australia, 3-7 Dec. 2000.

Oral Presentation: Evidence for alternate translation within the core coding region of the hepatitis C virus.

Varaklioti R., Georgopoulou U., Vassilaki N. and Mavromara P.

FOREIGN LANGUAGES

English (Certificate of Proficiency in English), French (DELF, DALF)

TABLE SUMMARIZING PUBLICATIONS

Journal/ Book	Number of Publication	Hetero citations	Impact Factor 2016	Series of author's name, Corresponding author, Principal Investigator (PI)	Hirsch number (h-index)
Journal of Virology	7, 14, 16	56, 21, 2	5.308, 4.648, 4.606	1/9, 1/18 corresponding and PI, 3/6	13
Journal of General Virology	5, 12, 13	4, 16, 9	3.092, 3.363, 3.529	1/3, 2/14, 2/7 corresponding and PI	
Virus Research	6, 10	10, 8	2.429, 2.941	1/3, 2/9	
Journal of Clinical Virology	27	-	2.630	2/5	
Viral Oncogenesis	3 (Review)	-	-	1/3	
Microbes and Infection	19 (Review)	2	2.924	1/2 corresponding	
Cells	22	-	5.656	11/11, corresponding and PI	
Cells	27	-	5.656		
PLoS One	11	11	4.092	8/12	
Journal of Biological Chemistry	1, 2	101, 42	6.696, 6.482	2/4, 1/2	
Biochimie	24	-	3.188	8/8 corresponding and PI	
FEBS Journal	4, 9, 29-36	7, 9, -	3.396, 3.129, 3.139, 3.139, 3.139, 3.139, 3.042, 3.790, 4.250, 4.001	1/3, 5/9, 1/5, 3/5, 2/3, 2/7, 5/9, 2/3, 2/3, 2/5	
The International Journal of Biochemistry & Cell Biology	17	3	3.505	3/5	13
Med. Chem. Comm.	18, 25	7, -	2.608, 2.342	10/11 PI article featured as: New Talent Europe, 2016 MedChemComm Hot	

				Article, Front cover 9/10 PI
Chem Biol Drug Des.	20	-	2.328	8/8 corresponding and PI
Arch Pharm (Weinheim)	21	-	2.288	3/8
ACS Omega	26	-		4/8
Hum Gene Ther	23	-	4.241	6/12
IUBMB Life	8 (Review)	28	3.578	1/2 corresponding
Reference Module in Biomedical Science	15 (Review)	-	-	2/2 corresponding
Total	31	336	122.29	
Average impact factor: $122.29/33= 3.71$				

Sources: ISI Web of Science, Scopus, Google books

Full-length publications: 27 (in Molecular Virology)

- Research papers in journals: **23**
- Reviews: **4** (journals and book)
- 1st Author: **9**
- Corresponding Author: **8**
- Principal Investigator in research papers: **7**

Published conference proceedings: 9

Quality factors of publications:

- h-index: **13**
- Total impact factor: **122.29**
- Average Impact Factor: **3.71**
- Hetero-citations: **336**

Patent and Provisional patent application: on the HCV core+1 protein

Presentations in conferences after reviewing:

- International Conferences: **61** (30 on International Symposiums on HCV)
- National Conferences: **28**
- Oral Presentations in international virology congresses: **5**, in international medicinal chemistry congress: **2**
- Oral Presentations in National conferences: **13**

Research programs funded:

- Coordination of **8** programs (**6** National and **2** International): Asklepios Gilead Sciences Hellas grant 2019-2020, Empeirikeion Foundation Research grant 2017-2018, IKY (State Scholarships Foundation) Doctoral

grant 2018-2019, Erasmus+ Traineeship 2018, Asklepios Gilead Sciences Hellas grant 2017-2018, International Pasteur Network grant ACIP 2015-2017, National grant LATSIS 2013-2014, German-Greek bilateral DAAD 2006-2007

- Participation as a Principal investigator of subprojects in **6** National programs, ESFRI- European Strategy Forum for Research Infrastructures, National Research & Innovation Infrastructures EATRIS-GR 2018-2020, KRIPIS II 2017-2019, KRIPIS 2013-2015, BIONIAN Cluster 2013-2015 and as a work package leader in ARISTEIA 2013-2015. Principal investigator of the HCV related subproject of the Asklepios Gilead grant 2016-2017

- Participation as a collaborating researcher in **4** programs: International PTR 2003-2006, European COMPUVAC 2004-2008, National THALES 2013-2015, Single RTDI State Aid Action RESEARCH - CREATE - INNOVATE 2018-2020 NanoVacLeish, Asklepios Gilead Sciences Hellas grant 2018-2019